AstraZeneca PLC · LSE:AZN
AstraZeneca — Technical Presentation (2000)
13 slides from AstraZeneca's technical presentation, 2000
Slide 1: AstraZeneca GI Franchise
A AstraZeneca GI Franchise Dr Hans Glise Vice President, Head of GI Area Leadership in GI “A growing portfolio in a growing segment” A Hans Glise - GI Page 1
Slide 2: Proton Pump Inhibitors vs global pharmaceutical market
Proton Pump Inhibitors vs global pharmaceutical market Average annual growth MAT Q2 1995–MAT Q2 2000 Average annual growth of sales (US$) % 35 30 25 20 15 10 5 0 PPIs Global Pharma Source: IMS Health 34 countries Ethical Market A AstraZeneca in GI Gastroesophageal Reflux Disease (GERD) Dyspepsia Pep
Slide 3: Prevalence of GI disorders
Prevalence of GI disorders % of Western world population 60 50 40 30 20 10 0 PUD GERD Dyspepsia IBS IBD A Gastroesophageal Reflux Disease (GERD) Esophageal b Mechanisms malfunction b Pathophysiology b Symptomatology – Mild-to-severe symptoms Acid Bile b Consequences – Poor quality of life – Decrease
Slide 4: Indirect and direct costs for GERD
Indirect costs for GERD % Reduced Weekly indirect cost untreated productivity moderate GERD US$ 50 500 Absence from work (2hrs) At work Reduced working 40 Daily activities 400 ability (8hrs) 30 300 238 20 200 183 10 100 0 0 55 None Mild Moderate Severe Symptom severity (n=136) Wahlqvist P, et al. Me
Slide 5: Cost of GERD; GERD treatment – AstraZeneca
Cost of GERD One year’s treatment A few weeks of untreated GERD Cost to society A GERD treatment – AstraZeneca 1. Acid inhibition – Losec / Prilosec ® ® – Nexium ® – Reversible acid pump inhibitor drug A Hans Glise - GI Page 5
Slide 6: Reversible acid pump inhibitor
GERD treatment – AstraZeneca 1. Acid inhibition – Losec / Prilosec ® ® – Nexium ® – Reversible acid pump inhibitor drug 2. Reflux inhibition – GABAB agonist A Reversible acid pump inhibitor Day 1 acid inhibition in healthy volunteers Acid output mmol HCl/15 min 8 Pentagastrin Low dose 30 µg/h i.v. M
Slide 7: Reversible acid pump inhibitor: intragastric pH
Reversible acid pump inhibitor Median intragastric pH in healthy volunteers and DU patients – first dose 7 Lunch Snack 6 5 Placebo Intragastric pH Medium dose 4 healthy volunteers 3 omeprazole 20 mg in DU patients 2 1 0 0 4 8 Time (hours) Data on File Adapted from Cederberg et al 1992 (omeprazole) A
Slide 8: Reflux inhibition
Reflux inhibition A Reflux inhibition Healthy volunteers GERD patients % TLESRs* accompanied 31% by reflux 69% 52% 48% % TLESRs* not accompanied by reflux * Transient lower esophageal sphincter relaxations Lidums et al., 2000; Holloway et al., 2000 A Hans Glise - GI Page 8
Slide 9: GABAB agonist reduces reflux episodes
Reflux inhibition GABAB agonist (Baclofen 40 mg – antispastic drug) significantly reduces the rate of reflux episodes in healthy volunteers and GERD patients 14 Number of reflux episodes/3h 12 Placebo 10 Baclofen p<0.02 8 6 p<0.02 4 2 0 Healthy Volunteers GERD Lidums et al., 2000; Holloway et al., 2
Slide 10: Reflux inhibitor dose response; Inflammatory Bowel Disease
Reflux inhibitor dose response Baclofen Reflux inhibitor 100 % inhibition of TLESR 50 “Therapeutic “Therapeutic range” reflux inhibitor range” Baclofen 0 0.1 10 1000 µmol/kg, p.o. A Inflammatory Bowel Disease (IBD) b Entocort® – US filing soon b Rofleponide – Potent effect, targeted to disease area
Slide 11: H. pylori
H. pylori b Medical background – gastric inflammation – peptic ulcer – gastric cancer A H. pylori b H. pylori-specific monotherapy – discovery phase b Immunotherapy – discovery phase A Hans Glise - GI Page 11
Slide 12: Summary – GI emerging portfolio
Summary – GI emerging portfolio Phase b Strong pipeline for the Discovery treatment of reflux disease and in man b Further improvement of locally acting In man corticosteroids in IBD b New principles of treatment for Discovery H. pylori infection b New principles of treating visceral Discovery hyper
Slide 13: The GI pipeline
The GI pipeline Losec® Entocort® Nexium® Reversible acid pump inhibitor Reflux inhibitor IBD corticosteroid H. pylori monotherapy H. pylori vaccines IBS concept (visceral hypersensitivity) A Hans Glise - GI Page 13